Dihydroergotamine
Ergotamine
Sumatriptan
Arteriovenous Anastomosis
Dihydroergocornine
Migraine Disorders
Hydroxyzine
Ergot Alkaloids
Serotonin Receptor Agonists
Receptor, Serotonin, 5-HT1B
Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. (1/61)
The antimigraine drugs methysergide, ergotamine and dihydroergotamine (DHE) produce selective vasoconstriction in the external carotid bed of vagosympathectomized dogs anaesthetized with pentobarbital and artificially respired, but the receptors involved have not yet been completely characterized. Since the above drugs display affinity for several binding sites, including alpha-adrenoceptors and several 5-HT1 and 5-HT2 receptor subtypes, this study has analysed the mechanisms involved in the above responses. Intracarotid (i.c.) infusions during 1 min of methysergide (31-310 microg min(-1)), ergotamine (0.56-5.6 microg min(-1)) or DHE (5.6-31 microg min(-1)) dose-dependently reduced external carotid blood flow (ECBF) by up to 46+/-4, 37+/-4 and 49+/-5%, respectively. Blood pressure and heart rate remained unchanged. The reductions in ECBF by methysergide were abolished and even reversed to increases in animals pre-treated with GR127935 (10 microg kg(-1), i.v.). The reductions in ECBF by ergotamine and DHE remained unchanged in animals pre-treated (i.v.) with prazosin (300 microg kg(-1)), but were partly antagonized in animals pre-treated with either GR127935 (10 or 30 microg kg(-1)) or yohimbine (1000 microg kg(-1)). Pre-treatment with a combination of GR127935 (30 microg kg(-1)) and yohimbine (1000 microg kg(-1)) abolished the responses to both ergotamine and DHE. The above doses of antagonists were shown to produce selective antagonism at their respective receptors. These results suggest that the external carotid vasoconstrictor responses to methysergide primarily involve 5-HT1B/1D receptors, whereas those to ergotamine and DHE are mediated by 5-HT1B/1D receptors as well as alpha2-adrenoceptors. (+info)Secretory responses to sympathetic stimulation of the cat's salivary glands in a state of resting secretion. (2/61)
The secretory effect of sympathetic stimulation on the cat's submaxillary gland was augmented greatly when studied against a background of slow secretion evoked by parasympathetic stimulation at a low frequency and imitating the slow resting secretion normally present in the waking state. The sympathetic secretory threshold was markedly lowered, and even at low frequencies sympathetic stimulation caused a large, well-maintained response. After an alpha-adrenoceptor blocking drug sympathetic stimulation alone lost its secretory effect, but during resting secretion part of the accelerating effect was found to remain; this effect was elicited via beta-adrenoceptors. A marked secretory effect of sympathetic stimulation was also obtained during resting secretion in the parotid gland, where the sympathetic secretory effect is normally very small. (+info)Newer intranasal migraine medications. (3/61)
Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies. Placebo-controlled clinical studies demonstrate that both intranasal forms are effective in relieving migraine headache pain, but published clinical trial information comparing these two intranasal medications with current abortive therapies is lacking. Both agents are generally well tolerated by patients, with the exception of mild, local adverse reactions of the nose and throat. (+info)Alternate numbness in the upper extremities as the initial symptom of basilar migraine: an electrophysiological evaluation using EEG power topography. (4/61)
A case of basilar migraine (BM) with alternate numbness as the initial symptom is described. The patient's chief complaint was alternate numbness in the right and left upper extremities. After angiography the patient fell into a drowsy state, followed by excitation, and finally confusion. The EEG power topography showed slow alpha, theta and delta power in the right occipital area, and alternatively in the right and left parietal area. These findings suggest that the cause of BM is not only based on a vasoconstriction mechanism, but also cortical spreading depression. BM should be suspected as a cause of sensory symptoms. (+info)Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. (5/61)
AIMS: To investigate the peripheral vascular effects and pharmacokinetics of dihydroergotamine (DHE) 0.5 mg after a single subcutaneous administration in humans. METHODS: A double-blind, placebo-controlled cross-over study was performed in 10 healthy male subjects. A wash-out period of 2 weeks separated the two study periods. During each period, just before and at regular intervals after drug administration, vascular measurements were performed and venous blood samples were drawn. Vessel wall properties were assessed at the brachial artery, by ultrasound and applanation tonometry. Blood pressure and heart rate were recorded with an oscillometric device. Forearm blood flow was measured with venous occlusion plethysmography. For all parameter-time curves the area under the curve (AUC) was calculated. Differences in AUC after placebo and DHE (DeltaAUC) were analysed and the time-course of the difference assessed. DHE pharmacokinetics were analysed according to a two-compartment open model with an absorption phase. RESULTS: AUC for blood pressure, heart rate and forearm vascular resistance did not change after DHE. Brachial artery diameter and compliance decreased (P < 0.01); DeltaAUC (95% confidence interval) equalled -8.81 mm h (-12.97/-4.65) and -0.98 mm2 kPa(-1) h (-1.61/-0.34), respectively. Diameter decreased (P < 0.05) from 1 until 24 h after DHE (peak decrease 9.7% at 10 h); compliance from 2 until 32 h (24.8% at 2 h). Time to reach maximum plasma concentration of DHE averaged 0.33 +/- 0.08 h (+/- s.e.mean); terminal half-life was 5.63 +/- 1.15 h. CONCLUSIONS: DHE decreased diameter and compliance of the brachial artery whereas forearm vascular resistance remained unchanged. Thus, DHE acts on conduit arteries without affecting resistance arteries. Furthermore, a discrepancy was demonstrated between the plasma concentrations of DHE which rapidly reach peak levels and quickly decline, and its long lasting vasoconstrictor activity. (+info)Haemodynamic effects of three doses of dihydroergotamine during spinal anaesthesia. (6/61)
We performed a randomized study comparing the haemodynamic effects of three doses of the vasopressor dihydroergotamine (DHE) (5, 10 and 15 microg x kg(-1)) in 30 ASA 1 and 2 patients, aged 53-87 yr, undergoing spinal anaesthesia. Non-invasive systolic arterial pressure (SAP), heart rate and central venous pressure (CVP) were recorded continuously for 25 min. Intravenous fluids were withheld during this period. All three doses of DHE reversed the lowering effects of spinal anaesthesia on SAP and CVP (P<0.0001), and these effects were smooth in onset and sustained. Whereas the lowest (5 microg x kg(-1)) dose restored SAP and CVP to near prespinal values, the higher (10 and 15 microg x kg(-1)) doses resulted in above-baseline increases in SAP of 7% and in CVP of 2.7 cm H2O (P<0.05). The haemodynamic profile of DHE makes it a useful agent for managing hypotension during spinal anaesthesia. A dose of 5-10 microg x kg(-1) is recommended. (+info)Cluster headaches associated with vascular malformations. (7/61)
A vascular malformation was demonstrated in a migrainous female who had developed cluster headaches. The patient responded well to oral dihydroergotamine 1 mg twice daily. (+info)The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. (8/61)
1. Peripheral lesion to the trigeminal nerve may induce severe pain states. Several lines of evidence have suggested that the antimigraine effect of the triptans with 5-HT(1B/1D) receptor agonist properties may result from inhibition of nociceptive transmission in the spinal nucleus of the trigeminal nerve by these drugs. On this basis, we have assessed the potential antinociceptive effects of sumatriptan and zolmitriptan, compared to dihydroergotamine (DHE), in a rat model of trigeminal neuropathic pain. 2. Chronic constriction injury was produced by two loose ligatures of the infraorbital nerve on the right side. Responsiveness to von Frey filament stimulation of the vibrissal pad was used to evaluate allodynia. 3. Two weeks after ligatures, rats with a chronic constriction of the right infraorbital nerve displayed bilateral mechanical hyper-responsiveness to von Frey filament stimulation of the vibrissal pad with a mean threshold of 0.38+/-0.04 g on the injured side and of 0.43+/-0.04 g on the contralateral (left) side (versus > or =12.5 g on both sides in the same rats prior to nerve constriction injury). 4. Sumatriptan at a clinically relevant dose (100 microg kg(-1), s.c.) led to a significant reduction of the mechanical allodynia-like behaviour on both the injured and the contralateral sides (peak-effects 6.3+/-1.1 g and 4.4+/-0.7 g, respectively). A more pronounced effect was obtained with zolmitriptan (100 microg kg(-1), s.c.) (peak-effects: 7.4+/-0.9 g and 3.2+/-1.3 g) whereas DHE (50-100 microg kg(-1), i.v.) was less active (peak-effect approximately 1.5 g). 5. Subcutaneous pretreatment with the 5-HT(1B/1D) receptor antagonist, GR 127935 (3 mg kg(-1)), prevented the anti-allodynia-like effects of triptans and DHE. Pretreatment with the 5-HT(1A) receptor antagonist, WAY 100635 (2 mg kg(-1), s.c.), did not alter the effect of triptans but significantly enhanced that of DHE (peak effect 4.3+/-0.5 g). 6. In a rat model of peripheral neuropathic pain, which consisted of a unilateral loose constriction of the sciatic nerve, neither sumatriptan (50-300 microg kg(-1)) nor zolmitriptan (50-300 microg kg(-1)) modified the thresholds for paw withdrawal and vocalization in response to noxious mechanical stimulation. 7. These results support the rationale for exploring the clinical efficacy of brain penetrant 5-HT(1B/1D) receptor agonists as analgesics to reduce certain types of trigeminal neuropathic pain in humans. (+info)Dihydroergotamine is a medication that belongs to a class of drugs called ergot alkaloids. It is a semi-synthetic derivative of ergotamine, which is found naturally in the ergot fungus. Dihydroergotamine is used to treat migraines and cluster headaches.
The drug works by narrowing blood vessels around the brain, which helps to reduce the pain and other symptoms associated with migraines and cluster headaches. It can be administered via injection, nasal spray, or oral tablet. Dihydroergotamine may cause serious side effects, including medication overuse headache, ergotism, and cardiovascular events such as heart attack or stroke. Therefore, it is important to use this medication only as directed by a healthcare provider.
Ergotamine is a type of ergopeptine alkaloid, derived from the ergot fungus (Claviceps purpurea) that parasitizes certain grains, particularly rye. It is a potent vasoconstrictor and has been used medically to prevent migraines and treat cluster headaches, as well as for other uses such as controlling postpartum hemorrhage and reducing symptoms of orthostatic hypotension.
Ergotamine works by binding to serotonin receptors in the brain and causing vasoconstriction of cranial blood vessels, which can help to relieve migraine headaches. However, it can also cause serious side effects such as nausea, vomiting, muscle pain, numbness or tingling in the extremities, and in rare cases, more severe reactions such as ergotism, a condition characterized by vasoconstriction of peripheral blood vessels leading to gangrene.
Ergotamine is usually taken orally, but can also be administered rectally or by inhalation. It is important to follow the dosage instructions carefully and avoid taking excessive amounts, as this can increase the risk of serious side effects. Ergotamine should not be taken during pregnancy or while breastfeeding, and it may interact with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting ergotamine therapy.
Sumatriptan is a selective serotonin receptor agonist, specifically targeting the 5-HT1D and 5-HT1B receptors. It is primarily used to treat migraines and cluster headaches. Sumatriptan works by narrowing blood vessels around the brain and reducing inflammation that leads to migraine symptoms.
The medication comes in various forms, including tablets, injectables, and nasal sprays. Common side effects of sumatriptan include feelings of warmth or hotness, tingling, tightness, pressure, heaviness, pain, or burning in the neck, throat, jaw, chest, or arms.
It is important to note that sumatriptan should not be used if a patient has a history of heart disease, stroke, or uncontrolled high blood pressure. Additionally, it should not be taken within 24 hours of using another migraine medication containing ergotamine or similar drugs such as dihydroergotamine, methysergide, or caffeine-containing analgesics.
An arteriovenous (AV) anastomosis is a connection or short channel between an artery and a vein that bypasses the capillary bed. In a normal physiological condition, blood flows from the arteries to the capillaries, where oxygen and nutrients are exchanged with the surrounding tissues, and then drains into veins. However, in an AV anastomosis, blood flows directly from the artery to the vein without passing through the capillary network.
AV anastomoses can occur naturally or be created surgically for various medical purposes. For example, they may be created during bypass surgery to reroute blood flow around a blocked or damaged vessel. In some cases, AV anastomoses may also develop as a result of certain medical conditions, such as cirrhosis or arteriovenous malformations (AVMs). AVMs are abnormal connections between arteries and veins that can lead to the formation of an AV anastomosis.
It is important to note that while AV anastomoses can be beneficial in certain medical situations, they can also have negative consequences if they occur inappropriately or become too large. For example, excessive AV anastomoses can lead to high-flow shunts, which can cause tissue damage and other complications.
Dihydroergocornine is a semi-synthetic ergot alkaloid, which is derived from the ergot fungus (Claviceps purpurea). It is a mixture of dihydroergocornine and dihydrocryptocornine. Dihydroergocornine acts as a partial agonist at alpha-adrenergic receptors, dopamine receptors, and serotonin receptors.
It has been used in the medical field for its vasoconstrictive properties to manage conditions such as orthostatic hypotension and cerebral vasospasm following subarachnoid hemorrhage. However, due to its potential for serious side effects, including ergotism, it is not commonly used today.
It's important to note that the use of Dihydroergocornine should be under the strict supervision of a medical professional and should only be used when the benefits outweigh the risks.
A migraine disorder is a neurological condition characterized by recurrent headaches that often involve one side of the head and are accompanied by various symptoms such as nausea, vomiting, sensitivity to light and sound, and visual disturbances. Migraines can last from several hours to days and can be severely debilitating. The exact cause of migraines is not fully understood, but they are believed to result from a combination of genetic and environmental factors that affect the brain and blood vessels. There are different types of migraines, including migraine without aura, migraine with aura, chronic migraine, and others, each with its own specific set of symptoms and diagnostic criteria. Treatment typically involves a combination of lifestyle changes, medications, and behavioral therapies to manage symptoms and prevent future attacks.
Hydroxyzine is an antihistamine medication that is primarily used to treat symptoms of allergies such as itching, hives, and swelling. It works by blocking the effects of histamine, a substance in the body that causes allergic reactions. In addition to its antihistaminic properties, hydroxyzine also has sedative and anxiety-reducing effects, which make it useful in treating anxiety disorders, symptoms of alcohol withdrawal, and as a sleep aid. It is available in both oral and injectable forms and is usually taken orally in the form of tablets, capsules, or syrup. As with any medication, hydroxyzine should be used under the supervision of a healthcare provider, and its use may be subject to certain precautions and contraindications depending on the individual's medical history and current health status.
Ergot alkaloids are a type of chemical compound that is produced naturally by certain fungi belonging to the genus Claviceps. These alkaloids are most famously known for being produced by the ergot fungus (Claviceps purpurea), which infects cereal grains such as rye and causes a condition known as ergotism in humans and animals that consume the contaminated grain.
Ergot alkaloids have a complex chemical structure and can have various effects on the human body. They are known to act as powerful vasoconstrictors, which means that they cause blood vessels to narrow and can increase blood pressure. Some ergot alkaloids also have psychoactive effects and have been used in the past for their hallucinogenic properties.
In modern medicine, certain ergot alkaloids are used in the treatment of various conditions, including migraines and Parkinson's disease. However, these compounds can be highly toxic if not used properly, and their use must be carefully monitored to avoid serious side effects.
Methiothepin is a non-selective, irreversible antagonist of serotonin (5-HT) receptors, particularly 5-HT1, 5-HT2, and 5-HT3 receptors. It has also been found to act as an antagonist at dopamine D2 receptors and histamine H1 receptors. Methiothepin has been used in research to study the roles of serotonin and other neurotransmitters in various physiological processes, but it is not commonly used clinically due to its lack of selectivity and potential for causing severe side effects.
Serotonin receptor agonists are a class of medications that bind to and activate serotonin receptors in the body, mimicking the effects of the neurotransmitter serotonin. These drugs can have various effects depending on which specific serotonin receptors they act upon. Some serotonin receptor agonists are used to treat conditions such as migraines, cluster headaches, and Parkinson's disease, while others may be used to stimulate appetite or reduce anxiety. It is important to note that some serotonin receptor agonists can have serious side effects, particularly when taken in combination with other medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs). This can lead to a condition called serotonin syndrome, which is characterized by symptoms such as agitation, confusion, rapid heart rate, high blood pressure, and muscle stiffness.
A serotonin receptor, specifically the 5-HT1B receptor, is a type of G protein-coupled receptor found in the cell membrane. It binds to the neurotransmitter serotonin (also known as 5-hydroxytryptamine or 5-HT) and plays a role in regulating various physiological functions, including neurotransmission, vasoconstriction, and smooth muscle contraction.
The 5-HT1B receptor is widely distributed throughout the body, but it is particularly abundant in the brain, where it is involved in modulating mood, cognition, and motor control. When serotonin binds to the 5-HT1B receptor, it activates a signaling pathway that ultimately leads to the inhibition of adenylyl cyclase, which reduces the production of cAMP (cyclic adenosine monophosphate) in the cell. This reduction in cAMP levels can have various effects on cellular function, depending on the specific tissue and context in which the 5-HT1B receptor is expressed.
In addition to its role as a serotonin receptor, the 5-HT1B receptor has also been identified as a target for certain drugs used in the treatment of migraine headaches, such as triptans. These medications bind to and activate the 5-HT1B receptor, which leads to vasoconstriction of cranial blood vessels and inhibition of neuropeptide release, helping to alleviate the symptoms of migraines.
Tryptamines are a class of organic compounds that contain a tryptamine skeleton, which is a combination of an indole ring and a ethylamine side chain. They are commonly found in nature and can be synthesized in the lab. Some tryptamines have psychedelic properties and are used as recreational drugs, such as dimethyltryptamine (DMT) and psilocybin. Others have important roles in the human body, such as serotonin, which is a neurotransmitter that regulates mood, appetite, and sleep. Tryptamines can also be found in some plants and animals, including certain species of mushrooms, toads, and catnip.
Vasoconstrictor agents are substances that cause the narrowing of blood vessels by constricting the smooth muscle in their walls. This leads to an increase in blood pressure and a decrease in blood flow. They work by activating the sympathetic nervous system, which triggers the release of neurotransmitters such as norepinephrine and epinephrine that bind to alpha-adrenergic receptors on the smooth muscle cells of the blood vessel walls, causing them to contract.
Vasoconstrictor agents are used medically for a variety of purposes, including:
* Treating hypotension (low blood pressure)
* Controlling bleeding during surgery or childbirth
* Relieving symptoms of nasal congestion in conditions such as the common cold or allergies
Examples of vasoconstrictor agents include phenylephrine, oxymetazoline, and epinephrine. It's important to note that prolonged use or excessive doses of vasoconstrictor agents can lead to rebound congestion and other adverse effects, so they should be used with caution and under the guidance of a healthcare professional.
Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.
There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.
Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.
Dihydroergotamine
Antimigraine drug
Ergotamine
Dihydrocodeine
Nitrovasodilator
Porphyria
Nasal administration
Migraine treatment
Migraine
Methysergide
Medicinal fungi
Ergoline
Triptan
Erythromycin
Indole alkaloid
Co-promotion
Discovery and development of triptans
Eletriptan
Trigeminovascular system
Fungal isolate
5-HT1D receptor agonist
Ketoconazole
Clarithromycin
List of MeSH codes (D03)
Brazilian Controlled Drugs and Substances Act
List of adrenergic drugs
5-HT1A receptor
DHE
List of drugs: Df-Di
Itraconazole
Dihydroergotamine - Wikipedia
Chemical Database: Dihydroergotamine Mesylate (EnvironmentalChemistry.com)
D. H. E. 45 (Dihydroergotamine): Uses, Dosage, Side Effects, Interactions, Warning
Dihydroergotamine by Sterimax Inc. - Uses, Side Effects, Interactions - MedBroadcast.com
Outlining migrainous through dihydroergotamine-serotonin receptor interactions using quantum biochemistry | ChemAxon
RePub, Erasmus University Repository: Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional...
Dihydroergotamine Nasal Spray (Trudhesa)
GLASS Ligand: Dihydroergotamine mesylate
The effects of dihydroergotamine on the... | ERA
8-Hydroxy dihydroergotamine-d5 - Labelled Compounds - Chemical catalogue
DailyMed - ERY-TAB- erythromycin tablet, delayed release
Dihydroergotamine (D.H.E. 45, Migranal) | Davis's Drug Guide
Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates
Why Up The Nose | Trudhesa® (dihydroergotamine mesylate) nasal spray | Official Website
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine | The Medical Letter Inc.
Neurologic Disease and Pregnancy: Overview, General Considerations, New-Onset Neurologic Complications
Quick-Acting Migraine Medication: What to Know
Selpercatinib (Oral Route) Description and Brand Names - Mayo Clinic
Allergy & Congestion Relief Advanced Patient Information - Drugs.com
Migraine Aura: Causes, Symptoms, Treatment & More
Neurologic Disease and Pregnancy: Overview, General Considerations, New-Onset Neurologic Complications
Prezcobix (Darunavir and Cobicistat Tablets): Uses, Dosage, Side Effects, Interactions, Warning
Ranolazine Advanced Patient Information - Drugs.com
Nitroglycerin (Transdermal Route) Side Effects - Mayo Clinic
Nonopioid Therapies for Pain Management | Healthcare Professionals | Opioids | CDC
Ocular migraine and COVID-19: What is the link?
Mifepristone (Korlym): MedlinePlus Drug Information
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual...
Mesylate13
- D.H.E. 45 (dihydroergotamine mesylate) is an ergot alkaloid used to treat a migraine or cluster headache attack. (rxlist.com)
- Our D.H.E. 45 (dihydroergotamine mesylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
- D.H.E. 45 (dihydroergotamine) ® is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. (rxlist.com)
- D.H.E. 45® (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. (rxlist.com)
- D.H.E. 45® (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. (rxlist.com)
- Available as a clear, colorless, sterile solution in single 1 mL sterile ampuls containing 1 mg of dihydroergotamine mesylate per mL, in packages of 10 (NDC 0078-0041-01). (rxlist.com)
- Serious cardiac events, including some that have been fatal, have occurred following use of D.H.E. 45® (dihydroergotamine mesylate) Injection, USP, but are extremely rare. (rxlist.com)
- Each mL of injectable solution contains dihydroergotamine mesylate 1 mg. (medbroadcast.com)
- Dihydroergotamine mesylate (DHE) has been available as a nasal spray (Migranal) since 1997. (reliasmedia.com)
- STOP 101: A phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 precision olfactory delivery (POD ®) device, in healthy adult subjects. (reliasmedia.com)
- STOP 301: A phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, precision olfactory delivery (POD ®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. (reliasmedia.com)
- Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. (mobilehealthtimes.com)
- Using Impel's proprietary Precision Olfactory Delivery (POD) technology, TRUDHESA gently delivers dihydroergotamine mesylate (DHE) quickly to the bloodstream through the vascular-rich upper nasal space. (mobilehealthtimes.com)
Ergotamine3
- Dihydroergotamine (DHE) is a semi-synthetic form of ergotamine approved in the US in 1946. (wikipedia.org)
- The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis. (whocc.no)
- In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors. (cdc.gov)
Nasal5
- One bottle of dihydroergotamine nasal spray contains 4 sprays. (medbroadcast.com)
- The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. (medicalletter.org)
- Another dihydroergotamine nasal spray (Migranal, and generics) has been available for. (medicalletter.org)
- The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks. (whocc.no)
- Satsuma Pharmaceuticals presented five abstracts highlighting STS101 (dihydroergotamine (DHE) nasal powder) for migraine. (biospace.com)
Trudhesa1
- Serious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Trudhesa) and strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. (trudhesa.com)
Migranal1
- Dihydroergotamine (DHE), sold under the brand names D.H.E. 45 and Migranal among others, is an ergot alkaloid used to treat migraines. (wikipedia.org)
Formulation of dihydroergotamine2
- LEVADEX contains a novel formulation of dihydroergotamine (DHE). (prnewswire.com)
- PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. (abc4.com)
Ergot alkaloids1
- Dihydroergotamine belongs to a family of medications called ergot alkaloids . (medbroadcast.com)
Monomethanesulfonate1
- D.H.E. 45 (dihydroergotamine) ® is known chemically as ergotaman-3',6',18-trione,9,10-dihydro-12'-hydroxy-2'-methyl-5'- (phenylmethyl) (5' a )-, monomethanesulfonate. (rxlist.com)
Migraine headache2
- Dihydroergotamine is most effective if used at the first sign of a migraine headache with or without aura (warning signs that occur prior to the onset of a migraine headache). (medbroadcast.com)
- The recommended dose of dihydroergotamine is one spray in each nostril (total of 2 sprays) at the first sign or symptom of a migraine headache, or as early as possible after the onset of migraine headache pain. (medbroadcast.com)
Inpatient2
- The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes. (neurologylive.com)
- Effect of Dihydroergotamine Infusion Rate on Inpatient Headache Treatment Outcomes. (neurologylive.com)
Protease1
- Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (rxlist.com)
Antimigraine2
- In this context, by taking advantage of its first crystallographic structure co-crystallized with dihydroergotamine (DHE), one of the oldest and largely used antimigraine drugs, a quantum biochemistry study based on the electrostatically embedded molecular fractionation with conjugate caps (EE-MFCC) scheme within the density functional theory (DFT) formalism is performed to unveil this complex's detailed binding energy. (chemaxon.com)
- INTRODUCTION: Dihydroergotamine (DHE) is a derivative of an ergot alkaloid used as an antimigraine medication. (bvsalud.org)
Infusion1
- Because dihydroergotamine (DHE) is a costly infusion, encounters at which DHE was administered were analyzed separately. (bvsalud.org)
Derivative1
- Dihydroergotamine, a derivative, can be used in treating migraine. (britannica.com)
Treat migraine1
- BACKGROUND: Dihydroergotamine (DHE) has long been used to treat migraine, but intravenous administration is invasive, frequently associated with adverse events (AEs), and not suitable for at-home administration. (bvsalud.org)
Treatment3
- Three concentrations of dihydroergotamine (DHE) were injected into embryos of 3 treatment groups (1μg/ml, 0.1 μg/ml, and 0.01μg/ml), at 1ml each. (ualberta.ca)
- Dihydroergotamine (DHE) has been used in the treatment of migraine for quite a long period of time, and in recent years, the interest in attempting to optimize this oft used but somewhat unchanged therapy has increased. (neurologylive.com)
- Dihydroergotamine, which is also used in the treatment of hypotension, is classified in this group. (whocc.no)
Drug1
- www.drugguide.com/ddo/view/Davis-Drug-Guide/109044/all/dihydroergotamine. (drugguide.com)
Heart1
- We have observed that as the concentration of dihydroergotamine increased there was greater damage to heart development, as reflected by the GAG-assay and observations of dissected embryos and hearts. (ualberta.ca)
Migraine13
- Dihydroergotamine is used to treat migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light) and cluster headaches (severe headaches usually on one side of the head or around one eye). (medlineplus.gov)
- Dihydroergotamine can be given subcutaneously at home to treat a migraine headache or given intramuscularly or intravenously at a doctor's office or hospital to treat a migraine or cluster headache. (medlineplus.gov)
- Dihydroergotamine should be used only to treat a migraine that is in progress. (medlineplus.gov)
- Do not use dihydroergotamine to prevent a migraine from beginning or to treat a headache that feels different than your usual migraine. (medlineplus.gov)
- The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT 1D receptors. (nih.gov)
- Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. (harvard.edu)
- Data from a single-center, retrospective cohort study published in Headache reported no significant cardiovascular adverse events (AEs) or EKG change among patients with a higher risk of ischemic events who were treated with dihydroergotamine (DHE) for their chronic migraine condition. (neurologylive.com)
- Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractor chronic migraine with cardiovascular risk factors: a retrospective study. (neurologylive.com)
- MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. (jefferson.edu)
- Dihydroergotamine and its use in migraine with posterior fossa symptoms. (jefferson.edu)
- Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. (jefferson.edu)
- For the treatment of migraine and to terminate an acute attack of cluster headache, dihydroergotamine mesylate is usually given by subcutaneous or intramuscular injection in doses of 1 mg repeated, if necessary, after 30 to 60 minutes up to a maximum daily dose of 3 mg. (pocketdrugguide.com)
- The usual nasal dose of dihydroergotamine mesylate for an acute migraine attack is 500 micrograms sprayed into each nostril as a 0.4% solution, followed after 15 minutes by an additional 500 micrograms in each nostril. (pocketdrugguide.com)
Orally Inhaled Dihydroergotamine1
- Cite this: Orally Inhaled Dihydroergotamine - Medscape - May 01, 2011. (medscape.com)
Headache4
- Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review. (harvard.edu)
- Fridinger S and Szperka C. Intravenous dihydroergotamine associated chest pain in pediatric headache patients. (chop.edu)
- Fridinger S and Szperka C. Effectiveness of intravenous dihydroergotamine for pediatric headache: Does headache diagnosis matter? (chop.edu)
- Fridinger S and Szperka C. The cardiovascular impact of intravenous dihydroergotamine for pediatric headache patients. (chop.edu)
Dose of dihydroergotamine1
- You may receive your first dose of dihydroergotamine in your doctor's office so that your doctor can monitor your reaction to the medication and be sure that you know how to use the nasal spray or administer the injection correctly. (medlineplus.gov)
Methysergide1
- Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT 1 agonists. (empr.com)
Mesylate injection1
- Dihydroergotamine Mesylate Injection, USP is a clear, colorless solution supplied in sterile ampules for intravenous, intramuscular, or subcutaneous administration. (nih.gov)
Semisynthetic ergot alkaloid1
- Dihydroergotamine (DHE) is a semisynthetic ergot alkaloid derived from the fungus Claviceps purpurea . (medscape.com)
Injection3
- Only 6% to 7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. (nih.gov)
- Peak plasma-dihydroergotamine concentrations have been attained within 1 to 2 hours after oral doses, 30 minutes after intramuscular injection, 15 to 45 minutes after subcutaneous injection, and 45 to 55 minutes after intranasal doses. (pocketdrugguide.com)
- Dihydroergotamine is commonly used as the mesylate by subcutaneous, intramuscular, or intravenous injection, although it may also be given as a nasal spray or orally. (pocketdrugguide.com)
Drugs1
- We also report that pergolide and dihydroergotamine, two drugs recently demonstrated to induce VHD in humans, potently activate 5-HT2B receptors, thus validating this assay system for its ability to predict medications that might induce VHD. (erowid.org)
Eletriptan2
- dihydroergotamine, eletriptan. (medscape.com)
- Caffox, Cafergot) or dihydroergotamine within 24 hours after taking eletriptan. (snec.com.sg)
Medications1
- Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. (nih.gov)
Bioavailability2
- Absolute bioavailability for the subcutaneous and intramuscular route have not been determined, however, no difference was observed in dihydroergotamine bioavailability from intramuscular and subcutaneous doses. (nih.gov)
- Although dihydroergotamine is incompletely absorbed from the gastrointestinal tract, the low bioavailability is determined primarily by extensive first-pass hepatic metabolism. (pocketdrugguide.com)
Hepatic9
- atazanavir will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- clarithromycin increases toxicity of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- erythromycin base will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- idelalisib will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- imatinib increases levels of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- indinavir will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- isoniazid will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
- itraconazole will increase the level or effect of dihydroergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
Receptors1
- Dihydroergotamine binds with high affinity to 5-HT 1D α and 5-HT 1D β receptors. (nih.gov)
Intranasal1
- Intranasal dihydroergotamine was found to be superior to placebo, but less effective than subcutaneous and intranasal sumatriptan. (nih.gov)
Oxytocic1
- In addition, dihydroergotamine possesses oxytocic properties. (nih.gov)
CYP3A42
- Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (nih.gov)
- Because CYP3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. (nih.gov)
Headaches1
- Dihydroergotamine (DHE) is a medication used to treat migraines and cluster headaches. (pocketdrugguide.com)
Descriptor1
- Dihydroergotamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
Medication1
- Be sure that you and anyone who will be helping you inject the medication read the manufacturer's information for the patient that comes with dihydroergotamine before using it for the first time at home. (medlineplus.gov)
Bound2
- Dihydroergotamine mesylate is 93% plasma protein bound. (nih.gov)
- Dihydroergotamine is 90 to 95% bound to plasma proteins. (pocketdrugguide.com)
Profiles3
- Pharmacokinetic profiles of dihydroergotamine formulations. (medscape.com)
- This graph shows the total number of publications written about "Dihydroergotamine" by people in Harvard Catalyst Profiles by year, and whether "Dihydroergotamine" was a major or minor topic of these publication. (harvard.edu)
- Below are the most recent publications written about "Dihydroergotamine" by people in Profiles. (harvard.edu)